HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This Phase1, open-label and dose-escalation study will evaluate the safety, tolerability,
pharmacokinetics, and preliminary anti-tumor efficacy of HLX07 administered as a single-agent
by IV infusion every 3 weeks to patients with locally advanced or metastatic solid
malignancies, who have failed or are intolerant to standard therapy, or for whom no standard
therapy is available.